This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Considerations on Pediatric Investigation Plans (PIP) for Advanced Therapy Medicinal Products
Published on: Oct 10, 2011
In Europe, advanced therapy medicinal products (ATMPs) are subject to the requirements laid down in the Paediatric Regulation. A company developing an ATMP must, therefore, obtain agreement from the EMA on a paediatric investigation plan (PIP) or waiver prior to submitting its marketing authorisation application (MAA).
David Uguen, Cecile de Coster
Considerations on paediatric investigation plans for advanced therapy medicinal products, TOPRA Vol 8, No.10
2011 – Regulatory Rapporteur